Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Saint Luke's Hospital — Chesterfield, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- University of Missouri Children's Hospital — Columbia, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Parkland Health Center - Farmington — Farmington, Missouri
- University Health Truman Medical Center — Kansas City, Missouri
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Missouri: - Research Site — Chesterfield, Missouri
- Research Site — Springfield, Missouri
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Missouri: - MidAmerica Cancer Care, LLC ( Site 0043) — Kansas City, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Missouri: - St. Luke's Hospital — Chesterfield, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Missouri: - MidAmerica Cancer Care, LLC ( Site 5426) — Kansas City, Missouri
Phase 3 Recruiting Industry
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primar…
Sponsor: Kite, A Gilead Company
NCT ID: NCT07479797
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Missouri: - University of Missouri Children's Hospital — Columbia, Missouri
- Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Siteman Cancer Center at Christian Hospital — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in Missouri: - Saint Luke's Hospital — Chesterfield, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Mercy Hospital Springfield — Springfield, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
Phase 2 Recruiting Industry
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…
Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in Missouri: - University of Missouri - Ellis Fischel Cancer Center — Columbia, Missouri
- MidAmerica Cancer Care — Kansas City, Missouri
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
Phase 2 Recruiting Industry
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…
Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in Missouri: - Washington University, St. Louis — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Missouri: - Children's Mercy Hospital — Kansas City, Missouri
Phase 2 Recruiting Industry
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…
Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in Missouri: - Research Site — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Missouri: - Washington University School of Medicine Siteman Cancer Center — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignan…
Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Missouri: - Children's Mercy Hospital ( Site 1024) — Kansas City, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT07015242
Sites in Missouri: - Washington University School of Medicine in St. Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Sponsor: BeOne Medicines
NCT ID: NCT06697184
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition i…
Sponsor: Mayo Clinic
NCT ID: NCT05388006
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Academic/Other
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of …
Sponsor: Washington University School of Medicine
NCT ID: NCT06687772
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Siteman Cancer Center at Christian Hospital — St Louis, Missouri